A Double-Blind, Randomized, Cross-Over Single-Dose Study to Compare the Pharmacokinetics, Safety, and Tolerability Following Administration of Palovarotene in Healthy Japanese and Non-Asian Subjects
Latest Information Update: 24 Feb 2023
At a glance
- Drugs Palovarotene (Primary)
- Indications Fibrodysplasia ossificans progressiva
- Focus Pharmacokinetics
- Sponsors Clementia Pharmaceuticals
- 18 Feb 2023 Results published in the European Journal of Drug Metabolism and Pharmacokinetics
- 05 Apr 2021 New trial record